NODE N.07 / ABOUT
A network-routed reading of the published record.
What this site is, what it is not, and why the 'order' modifier is editorial framing rather than a service claim.
What this site is
CJC-1295 / Order routes the peer-reviewed research on CJC-1295 into a navigable map of findings — twenty nodes wired together by directed edges that run from mechanism, through the Phase 1 pharmacokinetics, through the halted Phase 2 program, through the detection methods, out to the regulatory status. Reading the record as a connected graph is the whole argument of the page: the compound's story branches and loops rather than running in a straight line, so you follow the links between findings instead of scrolling one long essay.
What the papers actually cover is a compact set — a pair of early-phase human trials, a single discontinued mid-phase program, a scatter of analytical-chemistry work, a few animal models. Small enough to chart in full. The trouble is everything piled on top of it: message boards and sales pages that garble what was given to whom, fold the with-DAC and no-DAC forms into one, or bolt on dosing schemes no study ever ran. A map that goes back to the primary papers, pins each finding to its DOI, and lets the reader trace the wiring earns its keep as a fixed point of reference.
What this site is not
This is a reading room, not a point of sale. Nobody here writes prescriptions, and there is no clinical staff standing behind the page who could. Nothing is made, stocked, shipped, or sold — not CJC-1295, not any other compound — and there is no order desk, no checkout, no payment rail, and no supply arrangement behind the word in the domain. The publisher keeps no tie to any pharmacy, telehealth operation, manufacturer, distributor, or research-chemical seller, and steers readers to none of them.
The 'order' in cjc1295order.com names a structure, not a transaction. CJC-1295's defining pharmacokinetic feature is that it joins the body's circulatory mesh via covalent albumin conjugation rather than passing through it as a free peptide. The Network Flow aesthetic that organizes this site is a structural reading of that fact: nodes, edges, hubs, and a directed graph of trial-program and regulatory relationships. 'Order' is the structural register, not a transaction.
Editorial method
Every page here is a reading of published science, and nothing else. Source material is the primary peer-reviewed literature indexed on PubMed and PMC, plus the ClinicalTrials.gov registry entry for NCT00267527 (the terminated Phase 2 program) and the WADA Prohibited List. Every quantitative claim — dose value, half-life range, study count, percentage change — cites a specific primary source by DOI or PubMed/PMC URL. The /references page lists all sources used.
We do not cite forum posts, anonymous blog content, vendor marketing pages, or secondary lifestyle-medicine summaries as sources for factual claims. Where the published record is silent or incomplete, the page says so. Where a study was halted before publication of its endpoints (NCT00267527), the page documents the halt and notes the absence of peer-reviewed outcome data. Where a mechanistic concern (such as IGF-1-mediated mitogenic risk) exists in adjacent literature but has not been directly studied for CJC-1295, the page documents the concern and notes the empirical gap [17].
Disclaimer, in plain language
CJC-1295 is not approved for human use by FDA, EMA, MHRA, TGA, PMDA, or any other regulatory authority for any indication. The compound is listed by name under Section S2 (subsection 2.3) of the World Anti-Doping Agency Prohibited List and is prohibited at all times for athletes under WADA jurisdiction. Nothing on this site constitutes medical advice, a dosing recommendation, or an invitation to use, acquire, or distribute the compound. The doses reported on /dosage are the doses administered to research subjects in named published studies — they are reported as research-context, not as protocols for any reader.
This site is a routed reading of the published science on CJC-1295. It runs no clinic and holds no tie to any vendor, pharmacy, telehealth operation, manufacturer, or distributor. The one-line footer on every page is that contract.